Buys
Open market- Shares
- Avg price
- Total value
Third Rock Ventures V, L.P. - 10%+ Owner at Rapport Therapeutics, Inc.
Insider Transactions and Holdings
- Entity Type
- Company
- Role
- 10%+ Owner
- Issuer Symbol
- RAPP on Nasdaq
- All Insider Reports
- All Insider Reports
Third Rock Ventures V, L.P. - trading volume in the past year for Rapport Therapeutics, Inc.
Sells
Open market- Shares
- -836,136
- Avg price
- $40.24
- Total value
- -$33,647,473
Net
Past year- Shares
- -836,136
- Share %
- -100%
- Total value
- -$33,647,473
Holdings reported by Third Rock Ventures V, L.P. for Rapport Therapeutics, Inc.
Form 4 holding
10%+ Owner
Rapport Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 6,299,097
- Estimated value
- $253,500,859
- Report date
- 11 May 2026
- Price
- $40.24
- Ownership
- Direct
Form 4 holding
10%+ Owner
Rapport Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 6,299,097
- Estimated value
- $253,500,859
- Report date
- 11 May 2026
- Price
- $40.24
- Ownership
- Direct
Form 4 holding
10%+ Owner
Rapport Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 6,299,097
- Estimated value
- $253,500,859
- Report date
- 11 May 2026
- Price
- $40.24
- Ownership
- Direct
Form 4 holding
10%+ Owner
Rapport Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 6,299,097
- Estimated value
- $253,500,859
- Report date
- 11 May 2026
- Price
- $40.24
- Ownership
- Direct
Form 4 holding
10%+ Owner
Rapport Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 6,299,097
- Estimated value
- $253,500,859
- Report date
- 11 May 2026
- Price
- $40.24
- Ownership
- Direct
Form 4 holding
10%+ Owner
Rapport Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 6,299,097
- Estimated value
- $253,500,859
- Report date
- 11 May 2026
- Price
- $40.24
- Ownership
- Direct
Form 4 holding
10%+ Owner
Rapport Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 969,218
- Estimated value
- $30,326,831
- Report date
- 11 May 2026
- Price
- $31.29
- Ownership
- By Third Rock Ventures VI, L.P.
Form 4 holding
10%+ Owner
Rapport Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 969,218
- Estimated value
- $30,326,831
- Report date
- 11 May 2026
- Price
- $31.29
- Ownership
- By Third Rock Ventures VI, L.P.
Form 4 holding
10%+ Owner
Rapport Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 969,218
- Estimated value
- $30,326,831
- Report date
- 11 May 2026
- Price
- $31.29
- Ownership
- By Third Rock Ventures VI, L.P.
Form 4 holding
10%+ Owner
Rapport Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 969,218
- Estimated value
- $30,326,831
- Report date
- 11 May 2026
- Price
- $31.29
- Ownership
- By Third Rock Ventures VI, L.P.
Form 4 holding
10%+ Owner
Rapport Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 969,218
- Estimated value
- $30,326,831
- Report date
- 11 May 2026
- Price
- $31.29
- Ownership
- By Third Rock Ventures VI, L.P.
Form 4 holding
10%+ Owner
Rapport Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 969,218
- Estimated value
- $30,326,831
- Report date
- 11 May 2026
- Price
- $31.29
- Ownership
- By Third Rock Ventures VI, L.P.
Form 4 holding
10%+ Owner
Rapport Therapeutics, Inc.
- Security class
- Series A Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 10 Jun 2024
- Price
- Ownership
- By Third Rock Ventures VI, L.P.
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
10%+ Owner
Rapport Therapeutics, Inc.
- Security class
- Series A Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 10 Jun 2024
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
10%+ Owner
Rapport Therapeutics, Inc.
- Security class
- Series B Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 10 Jun 2024
- Price
- Ownership
- By Third Rock Ventures VI, L.P.
- Underlying class
- Common Stock
- Underlying amount
Transactions reported by Third Rock Ventures V, L.P. for Rapport Therapeutics, Inc.
| Sym | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.